Founded in New York, Seelos Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for central nervous system (CNS) disorders and rare diseases. Their core mission is to address significant unmet medical needs, particularly in conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). Seelos Therapeutics aims to bring innovative therapies to market efficiently, focusing on improving the quality of life for patients suffering from these debilitating conditions.

Seelos Therapeutics has garnered attention from notable investors and media outlets due to its promising pipeline of treatments. The company has achieved significant milestones in its clinical trials, positioning itself as a key player in the biotech industry. By advancing novel therapeutic solutions, Seelos Therapeutics has made a substantial impact on the field of mental health and rare disease treatment, offering hope to patients and families affected by these challenging conditions.